Contact
Advancing the Treatment of Basel Cell Carcinoma and Glioblastoma
Princeton OncoTherapeutics has identified and patented a topical pharmaceutical compound for the treatment and prevention of basal cell carcinoma (BCC) and potential treatments for glioblastoma (GBM).
This naturally-derived compound has been standardized and purified using methods developed by Parimer Labs. Cell line assays versus no treatment and current therapy showed significant cytotoxicity for glioblastoma cell lines U251 and SF-268 and BCC cell line TE 354.T. Princeton Oncotherapeutics has recently applied for further evaluation using NCI’s 60 cell line screening methodologies.
NADPH
The compound targets NADPH (Nicotinamide adenine dinucleotide phosphate reduced). NADPH is a dinucleotide upregulated in all cancer cells to permit their rapid metabolism and reproduction. In vitro and in vivo assays conducted at various institutions support efficacy for BCC and certain cell lines of GBM. An investigator initiated clinical trial (IIT) protocol has been developed and the company is currently sourcing a clinic to conduct this trial. The compound has human use approval for topical application for indications other than BCC, providing a pathway for a repurposing approval and shortening of an FDA review process. Uses include first line treatment of BCC as a self-care/home use medicament; shrinkage of a tumor prior to Mohs or excision; maintenance of cancer-free skin; adjunct therapy for reduction in radiation dosage and frequency.
SCIENCE
Basal Cell Carcinoma
Princeton Oncotherapeutics believes that NADPH inhibition is an effective target for the topical treatment of basal cell carcinoma (BCC). Surprisingly, a non-irritating compound approved (monographed) for use in OTC products has been shown to diminish and resolve basal cell carcinomas with excellent cosmetic results. Use as a preventative is also foreseen. The use of this compound for treatment of BCC was recently awarded a US method and systems patent. International patent applications have also been filed.
Glioblastoma
An invitro, 60-cell line study of this compound at NIH’s National Cancer Institute showed virtually 100% effectiveness against two cell lines of glioblastoma. Princeton OncoTherapeutics sees potential in four areas for development: As an intra-tumoral first line treatment to shrink or eradicate the tumor; as a therapeutic dressing to the lining of the surgical cavity after excision of a glioblastoma; as an adjunct therapy for reducing tumor resistance to current pharmaceuticals by inhibiting adhesion of Type IV collagen, and as an adjuvant for sensitizing tumors to radiation therapy and reducing radiation recovery rate.
Our Mission: Advancement of Oncotherapies for BCC and Glioblastoma
Princeton Oncotherapeutics believes that BCC, the most common form of skin cancer, can be managed at both its early and more advanced stages with topical home care that is non-inflammatory and painless. We are also seeking investors and industry partners to utilize more sophisticated delivery vehicles for the control and possible cure of GBM, in both adjuvant and first line formulations.
Affiliated Research Organizations
Acknowledgements
